The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome

Genoveva Uzunova, Eric Hollander, Jason Shepherd

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Autism spectrum disorder (ASD) and Fragile X syndrome (FXS) are relatively common childhood neurodevelopmental disorders with increasing incidence in recent years. They are currently accepted as disorders of the synapse with alterations in different forms of synaptic communication and neuronal network connectivity. The major excitatory neurotransmitter system in brain, the glutamatergic system, is implicated in learning and memory, synaptic plasticity, neuronal development. While much attention is attributed to the role of metabotropic glutamate receptors in ASD and FXS, studies indicate that the ionotropic glutamate receptors (iGluRs) and their regulatory proteins are also altered in several brain regions. Role of iGluRs in the neurobiology of ASD and FXS is supported by a weight of evidence that ranges from human genetics to in vitro cultured neurons. In this review we will discuss clinical, molecular, cellular and functional changes in NMDA, AMPA and kainate receptors and the synaptic proteins that regulate them in the context of ASD and FXS. We will also discuss the significance for the development of translational biomarkers and treatments for the core symptoms of ASD and FXS.

Original languageEnglish (US)
Pages (from-to)71-98
Number of pages28
JournalCurrent Neuropharmacology
Volume12
Issue number1
StatePublished - 2014

Fingerprint

Ionotropic Glutamate Receptors
Fragile X Syndrome
Kainic Acid Receptors
Metabotropic Glutamate Receptors
Neuronal Plasticity
AMPA Receptors
Neurobiology
Medical Genetics
Brain
N-Methyl-D-Aspartate Receptors
Synapses
Neurotransmitter Agents
Proteins
Biomarkers
Communication
Autism Spectrum Disorder
Neurodevelopmental Disorders
Learning
Neurons
Weights and Measures

Keywords

  • AMPA receptor
  • Arc
  • Autism spectrum disorder
  • Fragile X syndrome
  • GRIP1/2
  • Kainate receptor
  • MAP1B
  • Memantine
  • Metabotropic glutamate receptor
  • Neuroligin
  • NMDA receptor

ASJC Scopus subject areas

  • Clinical Neurology
  • Pharmacology (medical)
  • Pharmacology
  • Neurology
  • Psychiatry and Mental health

Cite this

The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders : Autism Spectrum Disorders and Fragile X Syndrome. / Uzunova, Genoveva; Hollander, Eric; Shepherd, Jason.

In: Current Neuropharmacology, Vol. 12, No. 1, 2014, p. 71-98.

Research output: Contribution to journalArticle

@article{420ba059f70a4988a9ae2360077e3898,
title = "The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome",
abstract = "Autism spectrum disorder (ASD) and Fragile X syndrome (FXS) are relatively common childhood neurodevelopmental disorders with increasing incidence in recent years. They are currently accepted as disorders of the synapse with alterations in different forms of synaptic communication and neuronal network connectivity. The major excitatory neurotransmitter system in brain, the glutamatergic system, is implicated in learning and memory, synaptic plasticity, neuronal development. While much attention is attributed to the role of metabotropic glutamate receptors in ASD and FXS, studies indicate that the ionotropic glutamate receptors (iGluRs) and their regulatory proteins are also altered in several brain regions. Role of iGluRs in the neurobiology of ASD and FXS is supported by a weight of evidence that ranges from human genetics to in vitro cultured neurons. In this review we will discuss clinical, molecular, cellular and functional changes in NMDA, AMPA and kainate receptors and the synaptic proteins that regulate them in the context of ASD and FXS. We will also discuss the significance for the development of translational biomarkers and treatments for the core symptoms of ASD and FXS.",
keywords = "AMPA receptor, Arc, Autism spectrum disorder, Fragile X syndrome, GRIP1/2, Kainate receptor, MAP1B, Memantine, Metabotropic glutamate receptor, Neuroligin, NMDA receptor",
author = "Genoveva Uzunova and Eric Hollander and Jason Shepherd",
year = "2014",
language = "English (US)",
volume = "12",
pages = "71--98",
journal = "Current Neuropharmacology",
issn = "1570-159X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders

T2 - Autism Spectrum Disorders and Fragile X Syndrome

AU - Uzunova, Genoveva

AU - Hollander, Eric

AU - Shepherd, Jason

PY - 2014

Y1 - 2014

N2 - Autism spectrum disorder (ASD) and Fragile X syndrome (FXS) are relatively common childhood neurodevelopmental disorders with increasing incidence in recent years. They are currently accepted as disorders of the synapse with alterations in different forms of synaptic communication and neuronal network connectivity. The major excitatory neurotransmitter system in brain, the glutamatergic system, is implicated in learning and memory, synaptic plasticity, neuronal development. While much attention is attributed to the role of metabotropic glutamate receptors in ASD and FXS, studies indicate that the ionotropic glutamate receptors (iGluRs) and their regulatory proteins are also altered in several brain regions. Role of iGluRs in the neurobiology of ASD and FXS is supported by a weight of evidence that ranges from human genetics to in vitro cultured neurons. In this review we will discuss clinical, molecular, cellular and functional changes in NMDA, AMPA and kainate receptors and the synaptic proteins that regulate them in the context of ASD and FXS. We will also discuss the significance for the development of translational biomarkers and treatments for the core symptoms of ASD and FXS.

AB - Autism spectrum disorder (ASD) and Fragile X syndrome (FXS) are relatively common childhood neurodevelopmental disorders with increasing incidence in recent years. They are currently accepted as disorders of the synapse with alterations in different forms of synaptic communication and neuronal network connectivity. The major excitatory neurotransmitter system in brain, the glutamatergic system, is implicated in learning and memory, synaptic plasticity, neuronal development. While much attention is attributed to the role of metabotropic glutamate receptors in ASD and FXS, studies indicate that the ionotropic glutamate receptors (iGluRs) and their regulatory proteins are also altered in several brain regions. Role of iGluRs in the neurobiology of ASD and FXS is supported by a weight of evidence that ranges from human genetics to in vitro cultured neurons. In this review we will discuss clinical, molecular, cellular and functional changes in NMDA, AMPA and kainate receptors and the synaptic proteins that regulate them in the context of ASD and FXS. We will also discuss the significance for the development of translational biomarkers and treatments for the core symptoms of ASD and FXS.

KW - AMPA receptor

KW - Arc

KW - Autism spectrum disorder

KW - Fragile X syndrome

KW - GRIP1/2

KW - Kainate receptor

KW - MAP1B

KW - Memantine

KW - Metabotropic glutamate receptor

KW - Neuroligin

KW - NMDA receptor

UR - http://www.scopus.com/inward/record.url?scp=84896722575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896722575&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84896722575

VL - 12

SP - 71

EP - 98

JO - Current Neuropharmacology

JF - Current Neuropharmacology

SN - 1570-159X

IS - 1

ER -